Sovleplenib

Sovleplenib is an investigational new drug that is being evaluated by Hutchison MediPharma for the treatment of immune thrombocytopenia (ITP) and warm antibody autoimmune hemolytic anemia (WAIHA). It has also been shown preclinically to have activity against B-cell lymphoma. Sovleplenib is a tyrosine-protein kinase SYK inhibitor.
Wikipedia contributors, "Sovleplenib", Wikipedia, revision 1383472060, retrieved 20 November 2026, source, CC BY-SA 4.0.